Moody Lynn & Lieberson LLC raised its holdings in shares of Novartis AG (NYSE:NVS) by 4.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,298 shares of the company’s stock after buying an additional 175 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Novartis were worth $392,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Arden Trust Co purchased a new stake in Novartis during the second quarter valued at about $2,347,000. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Novartis by 66.3% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 11,621 shares of the company’s stock worth $1,061,000 after purchasing an additional 4,631 shares during the period. Regentatlantic Capital LLC boosted its holdings in shares of Novartis by 69.0% during the second quarter. Regentatlantic Capital LLC now owns 44,276 shares of the company’s stock worth $4,043,000 after purchasing an additional 18,071 shares during the period. Reilly Financial Advisors LLC boosted its holdings in shares of Novartis by 7.5% during the second quarter. Reilly Financial Advisors LLC now owns 126,587 shares of the company’s stock worth $11,559,000 after purchasing an additional 8,782 shares during the period. Finally, Atlantic Union Bankshares Corp boosted its holdings in shares of Novartis by 97.0% during the second quarter. Atlantic Union Bankshares Corp now owns 69,029 shares of the company’s stock worth $6,302,000 after purchasing an additional 33,987 shares during the period. Institutional investors and hedge funds own 11.85% of the company’s stock.
A number of research firms have recently weighed in on NVS. Zacks Investment Research lowered shares of Novartis from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a report on Friday, July 19th. Kepler Capital Markets lowered shares of Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Novartis in a report on Friday, July 5th. Liberum Capital upgraded shares of Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Finally, Argus increased their target price on shares of Novartis to $105.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. They noted that the move was a valuation call. Four research analysts have rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $90.63.
Novartis (NYSE:NVS) last released its quarterly earnings results on Thursday, July 18th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.20 by $0.14. Novartis had a net margin of 23.27% and a return on equity of 18.55%. The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the prior year, the firm earned $1.29 earnings per share. Novartis’s revenue was up 3.7% on a year-over-year basis. Analysts forecast that Novartis AG will post 5.06 earnings per share for the current year.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Read More: New Google Finance Tool and Screening Stocks
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.